Statins and LDL-C in Secondary Prevention—So Much Progress, So Far to Go-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Statins and LDL-C in Secondary Prevention—So Much Progress, So Far to Go

Published:2020-11-20 Issue:11 Volume:3 Page:e2025675
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Banach Maciej¹²,Penson Peter E.³⁴

Affiliation:

1. Department of Hypertension, Medical University of Lodz, Lodz, Poland

2. Polish Mother's Memorial Hospital Research Institute, Lodz, Poland

3. School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK

4. Liverpool Centre for Cardiovascular Science, Liverpool, UK

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2773162/banach_2020_ic_200193_1605213441.78262.pdf

Reference9 articles.

1. LDL-C: lower is better for longer—even at low risk.;Penson;BMC Med,2020

2. Interpretation of the evidence for the efficacy and safety of statin therapy.;Collins;Lancet,2016

3. Assessment of trends in statin therapy for secondary prevention of atherosclerotic cardiovascular disease in US adults from 2007 to 2016.;Yao;JAMA Netw Open.,2020

4. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.;Mach;Eur Heart J,2020

5. EU-Wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study.;Ray;Eur J Prev Cardiol,2020

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is LDL cholesterol associated with long-term mortality among primary prevention adults? A retrospective cohort study from a large healthcare system;BMJ Open;2024-03

2. Study of Lipid-Modifying Therapy Use and Risk Factor Management in Patients With Dyslipidemia in Duhok City/Kurdistan Region, Iraq;Cureus;2024-02-08

3. Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL‐ACS Data;Journal of the American Heart Association;2023-09-19

4. A Look to the Past - What Has Had the Biggest Impact on Lipids in the Last Four Decades? A Personal Perspective;Archives of Medical Science;2023-05-16

5. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial;The Lancet Diabetes & Endocrinology;2023-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3